Professional Information
A-Z Drug Facts > Azacitidine

Azacitidine

Pronouncation: (ay-za-SYE-ti-deen)
Class: DNA demethylation agent

Trade Names:
Vidaza
- Powder for injection, lyophilized 100 mg

Pharmacology

Feedback for Azacitidine

As a treatment for... Avg User Ratings [?]
Myelodysplastic SyndromeBe the first to rate it
Compare with other drugs.

Believed to cause hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in bone marrow.

Pharmacokinetics

Absorption

Rapidly absorbed after subcutaneous administration; C max of 750 ng/mL in 0.5 h. Subcutaneous bioavailability is 89% compared with IV administration.

Distribution

Mean Vd is approximately 76 L.

Elimination

Mean apparent subcutaneous Cl is 167 L/h and mean t ½ is approximately 41 min. After subcutaneous administration, mean urinary excretion is 50%. Mean elimination t ½ is 4 h.

Special Populations

Renal or hepatic function impairment, gender, age, race

Effects on pharmacokinetics have not been studied.

Indications and Usage

Treatment of myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

Unlabeled Uses

Refractory acute lymphocytic leukemia, refractory acute myelogenous leukemia.

Contraindications

Advanced malignant hepatic tumors; hypersensitivity to mannitol or azacitidine.

Dosage and Administration

Adults

IV/Subcutaneous Recommended starting dose is 75 mg/m 2 daily for 7 days, every 4 wk. Premedicate patient for nausea and vomiting. Increase dose to 100 mg/m 2 if no beneficial effect is seen after 2 treatment cycles and if no toxicity other than nausea and vomiting occurs. It is recommended that patients be treated for a minimum of 4 cycles. Treatment may be continued as long as patient continues to benefit.

Dosage Adjustments Based on Hematologic Laboratory Values
Adults

IV/Subcutaneous For patients with baseline WBC at least 3 × 10 9 /L, absolute neutrophil count (ANC) at least 1.5 × 10 9 /L, and platelets at least 75 × 10 9 /L at the start of treatment, adjust dose based on nadir counts for any given cycle as follows:

  • ANC less than 0.5 × 10 9 /L; platelets less than 25 × 10 9 /L, administer 50% of dose in next course.
  • ANC 0.5 to 1.5 × 10 9 /L; platelets 25 to 50 × 10 9 /L, administer 67% of dose in next course.
  • ANC more than 1.5 × 10 9 /L, platelets more than 50 × 10 9 /L; administer 100% of dose in next course.

For patients with baseline WBC less than 3 × 10 9 /L, ANC less than 1.5 × 10 9 /L, or platelets less than 75 × 10 9 /L at the start of treatment, base dose adjustments on nadir counts and bone marrow biopsy cellularity at time of nadir as follows, unless there is clear improvement in differentiation (percentage of mature granulocytes is higher and ANC is higher than at onset of course) at time of next cycle, in which case continue the dose of the current treatment.

  • WBC or platelet nadir percent decrease in counts from baseline is 50% to 75% and bone marrow biopsy cellularity at time of nadir is 30% to 60%, give 100% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is 50% to 75% and bone marrow biopsy cellularity at time of nadir is 15% to 30%, give 50% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is 50% to 75% and bone marrow biopsy cellularity at time of nadir is less than 15%, give 33% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is more than 75% and bone marrow biopsy cellularity at time of nadir is 30% to 60%, give 75% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is more than 75% and bone marrow biopsy cellularity at time of nadir is 15% to 30%, give 50% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is more than 75% and bone marrow biopsy cellularity at time of nadir is less than 15%, give 33% of dose in next course.
  • If a nadir as previously defined has occurred, give the next course of treatment 28 days after the start of the preceding course provided that both WBC and platelet counts are more than 25% above the nadir and rising. If a more than 25% increase above nadir is not seen by day 28, reassess counts every 7 days. If a 25% increase is not seen by day 42, treat the patient with 50% of the scheduled dose.
Dosage Adjustments Based on Renal Function and Serum Electrolytes
Adults

IV/Subcutaneous If unexplained reductions in serum bicarbonate levels to less than 20 mEq/L occur, reduce dosage by 50% on next course. If unexplained elevations of BUN or serum creatinine occur, delay the next cycle until values return to normal or baseline and reduce dose by 50% on next treatment course.

General Advice

Suspension
  • Reconstitute powder with 4 mL of sterile water for injection. Inject diluent slowly into vial then invert vial 2 to 3 times and gently rotate until a uniform suspension is obtained. Resulting suspension contains 25 mg/mL of azacitidine.
  • Draw contents into syringe. Divide doses more than 4 mL equally into 2 syringes.
  • Immediately prior to administration resuspend the contents by inverting syringe 2 to 3 times and gently rolling the syringe between the palms for 30 sec.
  • Rotate sites for each injection (eg, thigh, abdomen, upper arm). Give new injections at least 1 inch from an old site and never into areas where the site is tender, bruised, red, or hard.
IV Solution
  • Reconstitute the appropriate number of azacitidine vials to achieve the desired dose.
  • Reconstitute each vial with 10 mL of sterile water for injection. Vigorously shake or roll the vial until all solids are dissolved. The resulting solution will contain azacitidine 10 mg/mL. The solution should be clear.
  • Withdraw the required amount of azacitidine solution to deliver the desired dose and inject into a 50 to 100 mL bag of either sodium chloride 0.9% or Ringer's lactate.
  • Administer IV solution over a period of 10 to 40 min. Administration must be completed within 1 h of reconstitution.
  • The suspension is for subcutaneous administration.
  • The solution is for IV administration.
  • Azacitidine is incompatible with dextrose 5% solution, Hespan , or solutions containing bicarbonate.
  • Discard unused portions of vial. Do not save any unused portions for future use.
  • Azacitidine is a cytotoxic drug. Use caution when handling and preparing azacitidine suspension and solution.

Storage/Stability

Store unreconstituted vials at 59° to 86°F.

Suspension

Reconstituted suspension for subcutaneous use may be stored for up to 1 h at 77°F or up to 8 h between 36° and 46°F.

Solution

Reconstituted solution for IV administration may be stored at 77°F, but administration must be completed within 1 h of reconstitution.



Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Cardiovascular

Cardiac murmur (10%); tachycardia (9%); hypotension (7%); syncope (6%); atrial fibrillation, cardiac failure, cardio-pulmonary arrest, CHF, congestive cardiomyopathy, orthostatic hypotension (less than 5%).

CNS

Fatigue (36%); headache (22%); dizziness (19%); aggravated fatigue, anxiety, decreased appetite (13%); depression (12%); insomnia, malaise (11%); lethargy (8%); hypoesthesia (5%); confusion, convulsions, intracranial hemorrhage (less than 5%).

Dermatologic

Petechiae (24%); erythema (17%); pallor (16%); skin lesion (15%); rash (14%); pruritus (12%); increased sweating (11%); night sweats (9%); urticaria (6%); dry skin, skin nodule (5%); pruritic rash, pyoderma gangrenosum, skin induration (less than 5%).

EENT

Pharyngitis (20%); epistaxis (16%); nasopharyngitis (15%); rhinorrhea (10%); nasal congestion, postnasal drip (6%); streptococcal pharyngitis (less than 5%).

GI

Nausea (71%); vomiting (54%); diarrhea (36%); constipation (34%); anorexia (21%); abdominal pain (16%); abdominal tenderness (12%); upper abdominal pain (11%); gingival bleeding (10%); oral mucosal petechiae, stomatitis (8%); dyspepsia, hemorrhoids (7%); abdominal distention, loose stools (6%); dysphagia, mouth hemorrhage, tongue ulceration (5%); diverticulitis, GI hemorrhage, melena, perirectal abscess (less than 5%).

Genitourinary

Dysuria, UTI (8%); hematuria, loin pain, renal failure (less than 5%).

Hematologic-Lymphatic

Anemia (70%); thrombocytopenia (66%); leukopenia (48%); neutropenia (32%); febrile neutropenia (16%); lymphadenopathy (10%); hematoma (9%); aggravated anemia, postprocedural hemorrhage (6%); agranulocytosis, bone marrow depression, splenomegaly (less than 5%).

Hepatic

Cholecystectomy, cholecystitis (less than 5%).

Hypersensitivity

Anaphylactic shock, hypersensitivity (less than 5%).

Lab Tests

Hypokalemia (13%).

Local

Injection-site erythema (35%); ecchymosis (31%); injection-site pain (23%); injection-site bruising or reaction (14%); injection-site pruritus (7%); injection-site granuloma, injection-site pigmentation changes, injection-site swelling (5%); catheter-site hemorrhage, injection-site infection (less than 5%).

Metabolic-Nutritional

Decreased weight (16%); dehydration (less than 5%).

Musculoskeletal

Arthralgia (22%); myalgia (16%); muscle cramps (6%); aggravated bone pain, muscle weakness, neck pain (less than 5%).

Respiratory

Cough (30%); dyspnea (29%); exertional dyspnea (14%); upper respiratory tract infection (13%); crackles in lung, pneumonia, productive cough (11%); rales, wheezing (9%); decreased breath sounds (8%); pleural effusion, rhonchi (6%); atelectasis, exacerbated dyspnea, sinusitis (5%); hemoptysis, Klebsiella pneumonia, lung infiltration, pneumonitis, respiratory distress (less than 5%).

Miscellaneous

Pyrexia (52%); weakness (29%); rigors (26%); limb pain (20%); back pain, contusion, peripheral edema (19%); chest pain (16%); pitting edema (15%); pain (11%); herpes simplex (9%); cellulitis (8%); peripheral swelling, transfusion reaction (7%); chest wall pain, postprocedural pain (5%); bacterial infection, blastomycosis, general physical health deterioration, Klebsiella sepsis, leukemia cutis, limb abscess, sepsis, staphylococcal bacteremia, staphylococcal infection, systemic inflammatory response syndrome, toxoplasmosis (less than 5%).

Precautions

Monitor

Renal function

Ensure that renal function is evaluated prior to starting therapy and before each cycle. If unexplained elevations in BUN or creatinine occur, delay next cycle until values return to normal or baseline, and reduce the dose 50% on the next treatment course. Monitor for hematologic response.


Pregnancy

Category D .

Lactation

Undetermined.

Children

Safety and efficacy not established.

Elderly

Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Renal Function

Monitor for toxicity because azacitidine and its metabolites are primarily excreted by the kidneys.

Hepatic Function

Use with caution.

Hematologic

Neutropenia and thrombocytopenia may occur; monitor CBC.

Renal abnormalities

Elevated serum creatinine, renal failure, and death may occur.

Skin/Mucus membranes

Avoid contact with skin and mucus membranes. If accidental skin contact occurs, wash thoroughly with soap and water. If mucus membrane contact occurs, flush thoroughly with water. If eye contact occurs, flush eyes using standard irrigation techniques.

Use in men

Advise men to use effective contraception during treatment.

Overdosage

Symptoms

Bone marrow suppression, diarrhea, nausea, vomiting.

Patient Information

  • Advise patient that medication will be prepared and administered by health care provider in a health care setting.
  • Review dosing schedule with patient.
  • Advise patient to immediately report any of the following to health care provider: difficulty breathing; fever, chills, or other signs of infection; hives; pain, redness, or swelling at injection site; rash; unusual bleeding or bruising.
  • Advise patient to report any of the following to health care provider: persistent nausea, vomiting, or appetite loss; persistent or worsening general body weakness.
  • Caution men to use effective contraception during therapy.
  • Caution women of childbearing potential to avoid becoming pregnant during therapy.



More Azacitidine resources:

Drugs.com Vidaza

MedFacts Azacitidine

Micromedex Azacitidine - Includes detailed dosage instructions.

FDA Vidaza

Azacitidine Drug Interactions

Compare Azacitidine with other medications for the treatment of:

Myelodysplastic Syndrome

User Reviews:

0 comment(s) about Azacitidine


MedNotes
Related Drugs
By Class
miscellaneous antineoplastics
By Condition
Myelodysplastic Syndrome
Advertisement
Save bookmark to...